Wim H. Scheele

TL;DR: It is shown that teriparatide treatment results in an increase in bone mineral density and is a potentially useful therapy for osteoporosis in men.

TL;DR: Teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate in 146 postmenopausal women with osteoporosis.

TL;DR: Vertebral fracture risk reduction by teriparatide administration persists for at least 18 months after discontinuation of therapy, and post hoc analysis suggests that teripararatide treatment substantially reduced the increased risk of subsequent fracture in women who sustained a fracture during the FPT.

TL;DR: RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study.

TL;DR: A consensus process was initiated to provide recommendations for the clinical evaluation of potential therapies to augment fracture repair in patients with meta- and diaphyseal fractures.